We demonstrated that CNIH4 has a significant effect on GSC markers (CD144, CD44, and BMI1) via knocking down CNIH4 by using specific shRNAs, implying that CNIH4 as a definite therapeutic target in glioma stem cells. Here, CDH5 is linked to central nervous system cancer.